6] are predictors of disease progression, particularly among patients with pretreatment CD4 + cell counts !200 cells/mm 3 [3, 7, 8] . Whether there are clinical advantages to maintaining HAART for patients who have low CD4 + cell counts before treatment initiation and who do not have adequate immunologic or virologic responses to HAART, however, remains to be determined. To our knowledge, the only data regarding whether continuing HAART in spite of virologic failure may be clinically beneficial come from HIV treatment interruption studies [9, 10] . However, because discontinuing HAART induced considerable CD4 + cell loss [9, 10] and the reappearance of wild-type HIV [9] , these Downloaded from https://academic.oup.com/cid/article-abstract/42/6/878/287052 by guest on 22 November 2018 studies do not address whether HAART protects patients who have inadequate CD4 + cell counts against HIV disease progression.
We therefore performed a cohort study to address whether maintaining HAART for patients with late-stage HIV infection who are unable to generate adequate CD4 + cell count and viral load responses to HIV therapy offers some protection against the occurrence of new AIDS-related events (AEs). To evaluate this, we calculated incidence rates of new AEs in patients according to various CD4 + cell count responses to HAART and compared these rates with those for patients with similar CD4 + cell count responses to nucleoside agents from the pre-HAART era, as well as with rates from historic cohorts from this earlier period.
METHODS
We identified HIV-infected patients treated at the University of Michigan HIV Clinic who had a baseline CD4 + cell count !200 cells/mm 3 before initiating antiretroviral therapy (ART) in a pre-HAART period (period 1; 31 January 1990-31 December 1995) and a period during the HAART era (period 2; 31 January 1996-31 December 2004). Patients were enrolled in the cohort from the time therapy was initiated if they received at least 12 months of HIV therapy, regardless of their CD4 + cell count responses (period 1 and period 2) and their viral load responses (period 2 only). All 88 patients who were followed up during period 1 received either 1 (55 patients) or 2 (33 patients) nucleoside reverse transcriptase inhibitors (NRTIs); HAART, as defined by Department of Health and Human Services guidelines [11] , was used in treating all 214 patients who were followed up during period 2. Patient information extracted from an electronic database (Solutions Clinical Patient Management System) at baseline included age, sex, race, HIV risk factors, whether an AE (according to the 1993 Centers for Disease Control and Prevention AIDS Surveillance definition) [12] was present prior to initiation of ART, and CD4 + cell count (and HIV load levels during period 2). Data on markers of response to ART (i.e., CD4 + cell counts [and viral load levels during period 2] that were obtained during the course of routine University of Michigan HIV Clinic practice every 3-6 months), and occurrence of a new, previously undiagnosed AE (according to the 1993 Centers for Disease Control and Prevention AIDS Surveillance definition) [12] were extracted from an electronic database (Solutions Management System). CD4 + cell counts were determined using flow cytometry, and all values are reported as absolute values rather than as increments above baseline. HIV RNA levels were determined using an RT-PCR assay (Amplicor; Roche Diagnostics). This study was approved by the institutional review board of the University of Michigan Health System. Given the dynamic nature of CD4 + cell count responses to HAART, we selected an analysis that would assess the risk of a new AE according to CD4 + cell counts during specified time periods. For a given CD4 + cell count and viral load measurement after initiation of ART, persons were considered to be at risk for a newly diagnosed AE for 1-6 months after the time of the measurement. Because all but 5 patients had multiple values available during the 1-6-month time period preceding an AE for period 1 and period 2, we used an average of all CD4 + cell counts and viral load values measured during this period to account for any fluctuations of CD4 + cell count and viral load determinations that may have occurred during this time interval. For each time period, we classified CD4 + cell count and viral load responses to ART into separate categories to determine incidence rates and 95% CIs of AEs per 100 patient-years of ART according to specific categories of the CD4 + cell count and HIV load responses measured 1-6 months prior to the AE. Patients who developed a new AE were not censured and remained in the study, so multiple AEs for the same patient were possible. Thus, a patient who had multiple AEs and a significant increase in CD4 + cell count between the 2 events could shift from one category during the first AE to a different category for the second AE.
To determine the effect of HAART on clinical events, we compared incidence rates of AEs in patients from period 2 with those of patients from period 1 according to various CD4 + cell count categories using Cox proportionate multivariate analysis. We did not include death as an endpoint in our analysis, because the proportion of deaths among patients with AIDS in which an AE is not the underlying cause has increased from 46% in 1996 to 72% in 2002 [13] , indicating that death is no longer an accurate reflection of an AE [14] . We chose CD4 + cell count categories (!100 cells/mm 3 and 100-200 cells/mm 3 ) to match our results with historic cohorts with similar CD4 + cell count responses to ART in the pre-HAART era (see Results). We also determined incidence rates for patients from period 2 with very low CD4 + cell count responses (CD4 + cell count, !50 cells/mm 3 ) and viral load responses (viral load, 1100,000 copies/mL); we compared these rates to those for period 1 patients who were in the same CD4 + cell count strata, but not to those of historic cohorts (data identifying patients with CD4
+ cell counts !50 cells/mm 3 were, to our knowledge, not available for historic cohorts). To determine the effect of inadequate viral load responses on clinical events in patients from period 2, we compared incidence rates of AE according to various viral load strata within specified CD4 + cell count categories using Cox proportionate analysis. All statistical tests were 2-sided, and a P value !.05 was considered to be statistically significant. GPL statistical software, version 2, was used for all statistical analyses. We obtained AE rates of historic cohorts that were followed up during the period 1981-1995 (during the pre-HAART era) by searching the English literature using the Medline database to cross reference "opportunistic infection," "Mycobacterium avium complex" (MAC), "Pneumocystis carinii" (now jiroveci) pneumonia (PCP), "cytomegalovirus infections," "Candida esophagitis" (CE), "Lymphoma," and "Kaposi sarcoma [KS] with HIV/AIDS."
RESULTS
A total of 302 patients who received ART were included in the analysis (88 patients from period 1 and 214 from period 2). Table 1 compares the demographic data and clinical features at baseline for the 2 groups. It shows that there are no major differences in these features between the groups; the mean age (at observation) was 39 years for period 1 and 37 years for period 2. The majority of patients in period 2 were receiving 2 NRTIs and 1 protease inhibitor. . These illnesses were also the most common AEs in period 1, with MAC accounting for 15 (24%) of 63 episodes, PCP accounting for 12 (19%) of 63 episodes, and CE accounting for 8 (12%) of 63 episodes. Regarding events that could have been preventable, 9 (65%) of 14 patients who received a diagnosis of MAC were receiving prophylaxis with a macrolide agent, and 9 (88%) of 11 patients with PCP were receiving pneumocystis prophylaxis at the time of diagnosis during period 2. Similarly, during period 1, a total of 7 (47%) of 15 patients who received a diagnosis of MAC were receiving prophylaxis, and 10 (84%) of 12 patients with PCP were receiving pneumocystis prophylaxis at the time of diagnosis.
The incidence rates of AEs overall and of individual AEs among patients treated with ART in period 2, compared with period 1, was calculated according to CD4 + cell count cate- a Historic cohort AE incidence rate range was determined using data reported in the literature for studies conducted in a period prior to HAART (1982-1995) [13] [14] [15] [16] .
gories. Table 2 shows that, for patients who had CD4 + cell counts !100 cells/mm 3 , the incidence of AEs overall was significantly lower during period 2 (18 AEs per 100 person-years), compared with period 1 (65.2 AEs per 100 person-years; ); it was also lower than AE incidence rate ranges P p .001 obtained from historic cohorts followed up in the pre-HAART era (95-98 AEs per 100 person-years). Furthermore, as shown in ). In addition, as shown P p .01 in table 2, the incidence rates of each individual AE (MAC, PCP, KS, CE, and lymphoma) were lower for period 2, compared with period 1 and with historic cohorts, for patients with a CD4 + cell count !100 cells/mm 3 after therapy. Table 2 also shows that the overall incidence of AEs among patients who had a CD4 + cell count of 100-200 cells/mm 3 after treatment was also significantly lower during period 2 (7.8 AEs per 100 person-years), compared with period 1 (34.5 AEs per 100 person-years;
), and lower than that for a historic P p .001 cohort from the pre-HAART era (21-27 AEs per 100 personyears). Furthermore, as shown in table 3, even for a subgroup of period 2 patients with the most unfavorable virologic responses to HAART (viral load, 1100,000 copies/mL) within the category of patients with an after-treatment CD4 + cell count of 100-200 cells/mm 3 (14 patients), the AE rate (15.4 AEs per 100 person-years) was still lower than it was during period 1 ( ) and lower than it was for the historic cohort matched P p .04 with this CD4 + cell count response category. Although the mean incidence rates of each individual AE indicated in table 2 were lower for period 2, compared with period 1 and with historic cohorts for patients with after-treatment CD4 + cell counts of 100-200 cells/mm 3 , there was overlap in the 95% CI for lymphoma. Table 3 shows the incidence rates of AE for patients from period 2 who were treated with HAART according to various viral load strata within all CD4 + cell count categories. For patients receiving HAART who had a CD4 + cell count !100 cells/ mm 3 , there was no significant correlation between viral load and AE incidence. In contrast, for patients receiving HAART who had a CD4 + cell count of 100-200 cells/mm 3 , incidence rates of AE were significantly lower for patients who had a viral load !5000 copies/mL (2.5 AEs per 100 person-years), compared with patients who had a viral load у5000 copies/mL (6.6 AEs per 100 person-years) ( ). Similarly, among patients P p .02 receiving HAART who had a CD4 + cell count 1200 cells/mm 3 , incidence rates of AE were lower among patients with a viral load !5000 copies/mL (1.1 AEs per 100 person-years) than among patients with a viral load у5000 copies/mL (3.9 AEs per 100 person-years) ( ). P p .04 + cell count responses to ART in the pre-HAART era. The lower rate during the HAART era was not only observed for overall AEs, but also for individual AIDSassociated illness for which prophylaxis rates did not significantly differ between the 2 periods (e.g., PCP). Moreover, the rates were lower for AEs for which prophylactic agents are not routinely used or available (e.g., CE and KS). Consequently, different rates of prophylaxis use in the pre-HAART cohorts may not have accounted for the different AE rates observed in this study. In addition, although some historic cohorts were conducted during periods when nucleosides were not constantly used or combined-during 1982-1995 [15] , 1985-1993 [16] , 1991-1995 [17] , and 1992-1994 [18]-higher rates of AEs were also observed for patients with equivalent CD4 + cell count responses who were treated with NRTIs at the University of Michigan HIV Clinic from 1990-1995. The observational cohort design of this study did not allow us to directly assess whether it is more beneficial for a patient with inadequate responses to potent ART to continue to receive HAART rather than a mutation-selected NRTI regimen. Nonetheless, because potent ART was not available in period 1, HAART may have been responsible for the lower AE rates observed in period 2.
Our findings suggest that, in patients with inadequate CD4 + cell count and viral load responses to therapy (even including those patients with very low CD4 + cell count responses, among whom AE rates are likely to be highest), maintaining HAART may provide some benefit by protecting against new AEs. Furthermore, our data raise the possibility that HAART has protective effects against HIV disease progression that are independent of standard quantitative immunologic and virologic parameters used to monitor HIV therapy. One possible explanation for the protective effects of HAART in this setting is a reduced virulence of HIV in patients who had persistent viremia during therapy because of drug-resistant viruses [19] . Another possible explanation for our findings is that memory CD4 + cells, which increase in number as a result of HAART, may recognize antigens on previously acquired pathogens that persist in a latent state and consequently prevent clinical reactivation [20] . Because assays currently used to monitor HIV therapy would not detect these effects of HAART, future studies using CD4 + cell functional assays (such as assays to determine CD4 + cell proliferative responses against selected antigens in patients who do not respond to HAART) could be considered to test this possibility.
Our study population-patients who first receive HAART while they are in the late stages of HIV infection or who have inadequate responses to HIV treatment-is not uncommon. In fact, studies have reported that a high percentage of HIV infection diagnoses occur either within 12 months of an AIDS diagnosis (39% in one study [21] ) or concurrently with an AIDS diagnosis (27% in another study [22] ). Furthermore, an inability to mount ample immunologic responses to HAART is not infrequent. For example, according to one study [23] , 21% of patients with a baseline CD4 + cell count !200 cells/ mm 3 did not achieve a CD4 + cell count 1200 cells/mm 3 at 173 weeks of treatment, and according to another study [24] , 16% of patients with a baseline CD4 + count of 190 cells/mm 3 did not increase their CD4 + cell count to 1200 cells/mm 3 after 4 years of treatment. Moreover, virologic failure rates are especially high (varying from 20% to 70%) among patients who either are treatment-experienced or have low CD4
+ cell counts and high viral loads before starting treatment [25, 26] .
Our finding that inadequate virologic responses (viral load, 15000 copies/mL) significantly increased AE rates among patients with CD4 + cell counts 1100 cells/mm 3 is consistent with other reports that have identified viral load at various levels (11000 copies/mL [3] , 17000 copies/mL [4] , and 120,000 copies/mL [6] ) as predictive of disease progression. By identifying viral load as a risk factor for AE that is independent of CD4 + cell count 1100 cells/mm 3 , our study raises the possibility that patients with multidrug-resistant viruses who have limited ART options and who continue to receive a virologically failing regDownloaded from https://academic.oup.com/cid/article-abstract/42/6/878/287052 by guest on 22 November 2018 imen to sustain a CD4 + cell count boost [27] may be at risk for disease progression [19] . We cannot exclude the possibility that there is a correlation between inadequate viral load response and a CD4 + cell count !100 cells/mm 3 , because the sample size in our single-site study was too small to detect such a correlation; multicenter studies using a larger number of patients would be necessary to investigate this possibility.
A retrospective cohort study such as ours has a number of additional limitations, because possible differences in the cohorts may have influenced AE rates. For example, the unavailability of viral load data from the pre-HAART era raises the possibility that higher viral loads in both the period 1 group and the historic cohorts, compared with those in the period 2 group, may have been partly responsible for the higher pre-HAART AE rates for any given CD4 + cell count category. In addition, although rates were compared within CD4 + cell count response categories, the relatively blunted increases in CD4 + cell count in response to NRTIs in the pre-HAART era raises the possibility that prolonged durations of time preceding an AE within a specified CD4 + cell count range (in excess of the 6-month time period that was used in our study) may have affected AE rates. Finally, although table 1 shows that there are no major differences in demographic characteristics between the 2 groups and no difference in baseline AE rates prior to initiation of ART, other possible differences (such as possible higher rates of wasting in period 1) may have accounted for the differences in AE rates.
In summary, our study suggests that, even in patients with advanced immunosuppression and inadequate CD4 + cell count and viral load responses to HIV therapy, continuing HAART may reduce the incidence of new AEs. This information complements data from drug interruption studies that provide indirect evidence that continuation of HAART in spite of virologic failure may be clinically beneficial [9, 10] . Nonetheless, the incidence rates of new AEs remain higher in such patients than in patients who have favorable CD4
+ cell count and viral load responses to HAART. Thus, although our study suggests that there may be some value in maintaining HAART even for patients who have immunologic and virologic failure, it also stresses the continued need for development of new antiretroviral agents that have activity against drug-resistant HIV strains, in hope of sustaining the overall decrease in AIDSassociated illnesses that has been witnessed since the introduction of HAART [28] .
